Myers Reveals Details of Promising New Illuvien Trial

Dan Myers, CEO, discusses the promise and challenges facing the Alimera’s development of Illuvien for the treatment of DME. He shares results from the firm’s USER Study, an analysis of 130 patients who have been treated with Illuvien. Myers also reports a financial first for Alimera.